OSR Health (OSRHW) Non-Current Deferred Tax Liability (2024 - 2026)
OSR Health (OSRHW) posted Non-Current Deferred Tax Liability of $26.6 million for Q1 2026, down 1.74% sequentially from $27.0 million in Q4 2025, and down 5.52% YoY from $28.1 million in Q1 2025.
OSR Health (OSRHW) Non-Current Deferred Tax Liability (2024 - 2026) Analysis & Trends
OSR Health has reported Non-Current Deferred Tax Liability for 3 years, with the latest figure at $26.6 million in Q1 2026.
- Quarterly Non-Current Deferred Tax Liability fell 5.52% year-over-year to $26.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.6 million (down 5.52% YoY) and the FY2025 annual result came in at $27.0 million, down 3.62% from the prior year.
- Non-Current Deferred Tax Liability eased to $26.6 million in Q1 2026 per OSRHW's latest filing, from $27.0 million in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $30.4 million in Q2 2025 and troughed at $26.6 million in Q1 2026.
- A 3-year average of $28.0 million and a median of $28.1 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- The sharpest annual moves came in 2025 and 2026: Non-Current Deferred Tax Liability fell 3.62% in 2025, then dropped 5.52% in 2026.
- Over 3 years, Non-Current Deferred Tax Liability stood at $28.0 million in 2024, then decreased by 3.62% to $27.0 million in 2025, then slipped by 1.74% to $26.6 million in 2026.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $26.6 million, $27.0 million, and $28.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.97 Bn | 131.12 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.15 Bn | 77.15 Bn | 3.93 Bn |
| 3 | Argenx Se | 62.84 Bn | 57.65 Bn | 1.37 Bn |
| 4 | Moderna | 55.74 Bn | 50.60 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.53 Bn | 36.43 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.32 Bn | 8.93 Bn | 668.28 Mn |
| 8 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - |
| 9 | Insmed | 26.99 Bn | 25.83 Bn | 358.27 Mn |
| 10 | OSR Health | 1.40 Mn | 20.39 Mn | 86,605.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.55 Mn |
| Mar 31, 2026 | 26.55 Mn |
| Dec 31, 2025 | 27.02 Mn |
| Dec 31, 2025 | 27.02 Mn |
| Sep 30, 2025 | 28.09 Mn |
| Sep 30, 2025 | 28.09 Mn |
| Jun 30, 2025 | 30.38 Mn |
| Jun 30, 2025 | 30.38 Mn |
| Mar 31, 2025 | 28.10 Mn |
| Mar 31, 2025 | 28.10 Mn |
| Dec 31, 2024 | 28.04 Mn |
| Dec 31, 2024 | 28.04 Mn |